Literature DB >> 26932441

Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.

Steven D Rhodes1, Feng-Chun Yang2.   

Abstract

Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene. NF1 encodes the protein neurofibromin, which functions to negatively regulate Ras-activity. Approximately 50 % of NF1 patients develop osteopenia or osteoporosis, resulting in significantly increased rates of long-bone fracture and morbidity. While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggest that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models delineating a critical role for hematopoietic compartment, myeloid progenitors of NF1 (Nf1) haploinsufficient and their progeny-osteoclasts, in the pathogenesis of NF1 associated osteopenia/osteoporosis and discuss putative targets for future therapeutics.

Entities:  

Keywords:  Neurofibromatosis type 1; Osteoclasts; Osteoporosis; Therapies

Mesh:

Substances:

Year:  2016        PMID: 26932441     DOI: 10.1007/s11914-016-0298-z

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  64 in total

1.  Double inactivation of NF1 in tibial pseudarthrosis.

Authors:  David A Stevenson; Holly Zhou; Shadi Ashrafi; Ludwine M Messiaen; John C Carey; Jacques L D'Astous; Stephen D Santora; David H Viskochil
Journal:  Am J Hum Genet       Date:  2006-05-10       Impact factor: 11.025

2.  Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation.

Authors:  Eetu Heervä; Maria H Alanne; Sirkku Peltonen; Tommi Kuorilehto; Teuvo Hentunen; Kalervo Väänänen; Juha Peltonen
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

3.  Bone mineral density in children and adolescents with neurofibromatosis type 1.

Authors:  David A Stevenson; Laurie J Moyer-Mileur; Mary Murray; Hillarie Slater; Xiaoming Sheng; John C Carey; Bukhosi Dube; David H Viskochil
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

4.  Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1.

Authors:  A E Lin; P H Birch; B R Korf; R Tenconi; M Niimura; M Poyhonen; K Armfield Uhas; M Sigorini; R Virdis; C Romano; E Bonioli; P Wolkenstein; E K Pivnick; M Lawrence; J M Friedman
Journal:  Am J Med Genet       Date:  2000-11-13

5.  Transgenic mice that express Cre recombinase in osteoclasts.

Authors:  W S M Chiu; J F McManus; A J Notini; A I Cassady; J D Zajac; R A Davey
Journal:  Genesis       Date:  2004-07       Impact factor: 2.487

6.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

7.  Blood pressure and cardiovascular involvement in children with neurofibromatosis type1.

Authors:  Giuliana Lama; Luisa Graziano; Elvira Calabrese; Carolina Grassia; Pier Francesco Rambaldi; Fabrizio Cioce; Michele Adolfo Tedesco; Giovanni Di Salvo; Maria Esposito-Salsano
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

8.  Optic gliomas in children with neurofibromatosis type 1.

Authors:  R Listernick; J Charrow; M J Greenwald; N B Esterly
Journal:  J Pediatr       Date:  1989-05       Impact factor: 4.406

9.  The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.

Authors:  Xiaohua Wu; Shi Chen; Yongzheng He; Steven D Rhodes; Khalid S Mohammad; Xiaohong Li; Xianlin Yang; Li Jiang; Grzegorz Nalepa; Paige Snider; Alexander G Robling; D Wade Clapp; Simon J Conway; Theresa A Guise; Feng-Chun Yang
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

10.  Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Authors:  Jean de la Croix Ndong; Alexander J Makowski; Sasidhar Uppuganti; Guillaume Vignaux; Koichiro Ono; Daniel S Perrien; Simon Joubert; Serena R Baglio; Donatella Granchi; David A Stevenson; Jonathan J Rios; Jeffry S Nyman; Florent Elefteriou
Journal:  Nat Med       Date:  2014-07-06       Impact factor: 53.440

View more
  1 in total

1.  Unusual form of the distal bone defect of ulna with neurofibromatosis type 1: A case report.

Authors:  Yiguo Shen; Fangfang Chen
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.